Gilead Sciences has decided to end a phase 3 trial of magrolimab for higher-risk myelodysplastic syndromes (MDS) after an analysis suggested it would be futile to continue.
License from Gilead grants AbTherx worldwide rights to a novel human therapeutic antibody discovery platformMOUNTAIN VIEW and SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / AbTherx, Inc., a privately held
Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conference:
Jefferies Healthcare Conference on Wednesday, June 7 at 11:00am ET
The live. | May 25, 2023